Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tookad

- PMLiVE

Janssen reports positive real-world data for Tremfya in psoriatic arthritis

The IL-23 inhibitor holds approvals to treat certain psoriatic arthritis and plaque psoriasis patients

- PMLiVE

Janssen shares new clinical trial data on its psoriasis treatment Tremfya

The results were presented at the 2022 AAD Annual Meeting in March

- PMLiVE

Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

- PMLiVE

FDA accepts review to broaden GSK’s Zejula label

Seeks approval in advanced ‘all-comer’ ovarian cancer population

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

AZ, Merck’s Lynparza scores market-expanding clinical success

Positive phase 3 findings in ovarian cancer

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links